Drug Profile
Alpha-1 antitrypsin - Omni Bio Pharmaceutical
Alternative Names: p-AAT; Plasma-derived alpha 1 antitrypsin - Omni Bio PharmaceuticalLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator University of Colorado at Denver
- Developer Colorado State University; Omni Bio Pharmaceutical; University of Colorado at Denver; Virginia Commonwealth University
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Pancreatic elastase inhibitors; Trypsin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Anthrax; Graft-versus-host disease; HIV infections; Influenza virus infections; Myocardial infarction; Pneumonia; Tuberculosis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 09 Dec 2014 Interim efficacy, adverse events and pharmacodynamics data from a phase I/II trial in Graft-versus-host disease presented at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH-2014)
- 30 Apr 2014 Final efficacy, adverse events and pharmacodynamics data from a clinical trial in Type 1 diabetes mellitus released by Omni Bio Pharmaceutical
- 01 Dec 2013 Phase-I/II clinical trials in Myocardial infarction in USA (IV) (NCT01936896)